comprehensive -WSS

comprehensive

author：explore 2025-10-02 03:24:27 - browse：3612

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： STAT Virtual Event: ASCO Recap, Live!

hotspot

WSS

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Study: Why relieving medical debt did not improve financial outcomes

CMS should re

Teladoc has a new CEO, but challenges remain the same

focus

comprehensive

knowledge

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Cancer drug shortages should be causing more outrage

Roche to buy Carmot Therapeutics, developer of obesity drugs

Cancer drug shortages should be causing more outrage

Leukemia patients are helped by Syndax's new type of therapy

Wildfire smoke exposes gaps in outdoor worker protections

AI models in health care face new federal disclosure requirements

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The system is set up to fail children with medical complexity

entertainment

Stephen Quake on the Chan Zuckerberg quest to conquer disease

California wildfire smoke linked to 52,000 early deaths, study says

FDA needs staff influx to meet gene therapy needs, Marks says

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Health care court cases: Humana, Sutter, Novant

New report analyzes digital physical therapy solutions' effectiveness

focus

hotspot

entertainment

focus